Teva Pharmaceutical Industries Ltd
Teva Can Benefit by Acquiring Allergan Generics
The combined Teva–Allergan generics entity should have approximately 320 Abbreviated New Drug Applications (or ANDAs), including 110 first-to-file ANDAs (or FTF) in the US.
Teva Pharmaceutical: Earnings Trends and Recent Developments
Teva Pharmaceutical’s net income and diluted EPS in the first nine months of 2018 amounted to $541.0 million and $0.53, respectively.
What Analysts Recommend for Teva Pharmaceutical in 2017
Following the completion of its acquisition of Allergan’s Actavis Generics business on August 2, 2016, Teva Pharmaceutical plans to focus on realizing the deal’s synergies in 2017.
Why the Majority of Analysts Deem Novartis a ‘Buy’
Novartis met Wall Street analysts’ estimates for EPS (earnings per share) in 4Q16, reporting EPS of $1.12 as estimated but missing revenue estimates.
Teva Stock Has Risen Significantly since November Lows: What’s Next?
On January 5, 2018, Teva Pharmaceuticals (TEVA) closed at $19.2 per share, which was ~77% higher than its 52-week low of $10.8 reported on November 2, 2017.
What Are the Challenges for the Pharmaceutical Industry in Japan?
Japan is the second-largest individual pharmaceutical market in the world. It accounts for less than 10% of the total global pharma market.
What Does Valeant’s Institutional Ownership Look Like?
Of its total outstanding shares, Valeant Pharmaceuticals’ (VRX) institutional ownership stood at 69.2%.
Berkshire Hathaway Increased Its Stake in Teva Again
Teva stock has gained ~27.0% year-to-date on the back of the positive news that included product launches and study data.
This Space Presents a Market Opportunity for Valeant
In Valeant’s 2Q16 earnings, Xifaxan reported a year-over-year (or YoY) increase in monthly prescriptions of about 28.0%.
Investor Insights: Teva Pharmaceutical’s Valuation Multiples
On October 11, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 7.5x compared to the industry average PE of 11.5x.
Teva Is Expected to See a Fall in Its Profit Margins in 2017
Teva Pharmaceutical (TEVA) expects its 2017 non-generally accepted accounting principles (non-GAAP) earnings per share (or EPS) to fall in the range of $4.9–$5.3.
Teva Stock Rises on Strong 1Q18 Results, Outlook Up
Today, Teva Pharmaceutical Industries (TEVA) released its 1Q18 earnings results for the quarter that ended on March 31.
Yes, There Will Be Margin Erosion for Valeant in 2017
Of its three businesses, Bausch & Lomb’s share in Valeant Pharmaceuticals’ (VRX) overall EBITA (earnings before interest, tax, and amortization) was 32%.
Teva’s Granix Gets FDA Approval for Expanded Indication
Today, Teva Pharmaceutical Industries (TEVA) announced that its Granix (tbo-filgrastim) injection has received FDA approval for a new presentation and indication.
Competition Dynamics for Ajovy—Teva’s Migraine Drug
Approved by the FDA on September 14, Teva’s Ajovy has multiple competitors set to enter the market.
An Overview of Valeant Pharmaceuticals’ Performance in 1Q18
Valeant Pharmaceuticals (VRX) announced that it would change its name to Bausch Health Companies, which is expected to be effective in July.
Non-Opioid Pain Therapy Market Opportunity for Teva
The Trump administration proposed production cuts in some of the most abused opioid compounds by 10% next year.
What Analysts Recommend for Mylan before Q2 2018 Earnings
Mylan (MYL) plans to release its Q2 results on August 8. Thirteen of the 20 analysts covering the stock have given it a “buy” or “strong buy.”
Millennium Management adds new position in Anixter International
For 1Q14, Anixter’s results beat on earnings, but missed on revenue.
Teva’s Share of the US Generics Market Could Boost Its Stock
Teva Pharmaceutical Industries accounts for 18% of the US generic drug market. This share is significantly higher than those of Mylan, Novartis, and Pfizer.
FDA Rejects Mylan’s Generic Advair Again, Stock Falls
On June 13, Mylan (MYL) announced that the FDA did not approve its generic version of GlaxoSmithKline’s (GSK) Advair Diskus, an asthma drug and inhaler combination.
Rx for Growth? Why Generic Drugs Are Gaining Traction
Rx for Growth? The trillion-dollar pharmaceutical industry has historically been dominated by a few major companies that create and supply the most important branded prescriptions on the market. Recent trends, however, point to the growth of the newest pharma blockbusters: generics. Today, approximately 60% of Americans take prescription drugs;[1. “Trends in Prescription Drug Use Among […]
A Look at Teva’s Generic Drugs Research Pipeline
Teva Pharmaceutical Industries has the largest generics product pipeline in the industry. It has 325 applications that are awaiting FDA approval.
Four Key Deals: Analyzing Pfizer’s Impending Growth
Over the past year, Pfizer completed multiple acquisitions to restore its top line growth. They will offset the revenue decline and fuel Pfizer’s top line.
Teva Pharmaceutical’s Generic Medicines Segment in 4Q17
In 4Q17, Teva Pharmaceutical’s (TEVA) generic medicines segment reported revenues of $3.1 billion compared to $3.7 billion in 4Q16.
Inside the Double-Digit Fall for Mallinckrodt’s Specialty Generics Business in 2016
Specialty Generics’ contribution to Mallinckrodt’s net sales fell by 18% to $1 billion in 2016. The business had a 31% share in total net sales in 2016.
Central Nervous System Is Key to Teva’s Specialty Medicines
Revenues for Teva’s (TEVA) Specialty Medicines segment grew by 2.1% to $8,560 million in 2014, from $8,388 million in 2013.
Teva’s Copaxone Maintains Market Share amid Intense Competition
In fiscal 1Q18, Teva (TEVA) reported sales of $645 million for its multiple sclerosis drug, Copaxone, a sequential decline of ~21%.
Amarin and Teva Settle Vascepa Patent Litigation
On May 24, Teva stock rose ~2.3%, partly triggered by the news of its litigation settlement.
Teva’s Respiratory Drugs Contribute 11% to Specialty Medicines
Teva’s respiratory drugs franchise provides solutions for asthma, COPD, and allergic rhinitis. Respiratory drugs contributed nearly 11% of total revenues for Teva’s Specialty Medicines in 2014.
Teva’s Austedo Sales Continue to Gain Momentum in 2018
In 1Q18, Teva Pharmaceutical (TEVA) reported sales of $30 million from the sales of its Austedo drug.
Akorn’s Macro-Level Challenges in the Generic Drug Segment
Although generic drugs only account for 3% of the total healthcare costs in the US, regulators continue to be concerned about rising generic pricing.
The Latest on Fasinumab, a Teva-Regeneron Collaborative Drug
On October 17, 2016, Teva and Regeneron announced that the FDA had placed the Phase 2 study for fasinumab on clinical hold.
What’s behind Teva’s $706 Million Impairment Charges in 1Q18?
In 1Q18, Teva Pharmaceutical Industries (TEVA) recorded non-GAAP (generally accepted accounting principles) EPS (earnings per share) of $0.94 and net income of $954 million.
The Latest on TEVA’s Oncology Business
In 1H17, Teva Pharmaceutical’s (TEVA) oncology business generated revenues of ~$550 million, or ~9% lower YoY (year-over-year).
Teva Announces First-to-File Launch of Generic Cialis
Yesterday, Teva Pharmaceutical Industries (TEVA) announced the exclusive FTF (first-to-file) launch of the generic Cialis1 tablets in the US.
Will Valeant be Able to Manage Its Huge Debt?
With its acquisitions, Valeant’s long-term debt kept on swelling until it reached $30.2 billion at the end of 4Q15. It plans to repay $1.7 billion in 2016.
Analysts Cut Target Prices on MYL Stock after Its Q2 2018 Results
Mylan (MYL) reported its Q2 earnings on August 8. On August 13, 13 of 20 surveyed firms still held a “buy” or “strong buy” rating on MYL.
Expert Q&A: What to Know Before Investing in Generic Pharma? (Part 2)
(continued from Part 1) 4. What is the nature of the cash flows for generics companies? Stable, driven by a constant demand for prescription drugs? Or lumpy, driven by growth from drugs coming off patent? The larger companies in this sector tend to have stable, steadier cash flows due to established lineups of approved products. […]
Expert Q&A: What to Know Before Investing in Generic Pharma? (Part 1)
Market Realist analysts recently conducted a Q&A with experts from VanEck on the generic pharmaceutical industry, a space that has attracted investor interest due to upside potential from brand name drugs coming off patent, cost saving pressure in the healthcare industry, and increased worldwide demand for prescription drugs (for more on these topics, please see […]
Why the Patent Cliff Is a Key Driver of Generic Drug Growth
Over the last several years, patent cliffs have led to steep revenue losses for traditional pharmaceuticals as well as created a gateway for smaller companies to come to market with generics.
A Financial Overview of Bausch Health in October
Bausch Health’s (BHC) net revenues declined from $4.3 billion in H1 2017 to $4.1 billion in H1 2018, reflecting an ~5.0% year-over-year decline.
Which of Amgen’s Drugs Could Witness Muted Growth in 2016?
Wall Street analysts have projected that Xgeva’s revenues will reach about $1.6 billion in 2016, which represents a YoY growth of about 12.3% for Amgen.
Is Kodak Stock Worth Your Attention Right Now?
An Easier Way to Understand the Pharma Industry
In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.
Third Point believes Amgen’s acquisitions should have done more
Faced with expiring patents and increasing competition for its blockbuster drugs, Amgen acquired Onyx to benefit from the latter’s innovative oncology portfolio and pipeline.
Ignyta and Its Key Risks in 2018
In October 2017, Ignyta (RXDX) raised $150 million by issuing 10 million shares of its common stock.
What Are Mylan’s Key Growth Drivers in Fiscal 2019?
In fiscal 2018, Mylan (MYL) reported revenues of $11.43 billion, a YoY decline of 4%.
Pfizer and Mylan: Is Mega-Merger on the Horizon?
The Wall Street Journal first announced the probable merger of Pfizer’s (PFE) off-patent business with Mylan (MYL) on July 27.
What’s Pulling Down Teva Pharmaceutical Stock?
In the coming months, Teva Pharmaceutical will be facing a federal court trial in Cleveland related to multiple opioid abuse cases.
Teva Pharmaceutical Is Facing These Challenges in 2019
On its first-quarter earnings conference call, Teva Pharmaceutical (TEVA) reaffirmed its 2019 global sales guidance of $1.30 billion for its Copaxone franchise.
Ajovy and Austedo: Teva Pharmaceutical’s Growth Strategy
On April 2, Teva Pharmaceutical issued a press release announcing the European Union’s approval of its monthly and quarterly dosages of Ajovy for preventing migraines.
What Are Analysts Recommending for TEVA and ENDP in May?
On May 13, Teva Pharmaceutical (TEVA) closed at $12.23, 14.83% lower than its previous day’s close.
What Are Bausch Health’s Key Growth Drivers in 2019?
In its fourth-quarter earnings conference call, Bausch Health Companies (BHC) has highlighted its Bausch + Lomb/International segment and Salix segment as the key growth drivers for the company in fiscal 2018.
What Are Teva Pharmaceutical’s Key Growth Drivers in 2019?
On its fourth-quarter earnings conference call, Teva Pharmaceutical (TEVA) highlighted Ajovy and Austedo as its key growth drivers for 2019.
What Analysts Are Recommending for Teva Pharmaceutical This Month
On February 15, Teva Pharmaceutical (TEVA) closed at $17.98, 4.05% higher than its previous closing price.
Teva Pharmaceutical or Mylan: Which Has the Better Debt Profile?
In the first nine months of 2018, Teva Pharmaceutical (TEVA) reduced its net debt level by $3.9 billion to $27.6 billion.
Teva Pharmaceutical or Mylan: Which Is More Cost Optimal?
According to Teva’s 37th Annual J.P. Morgan Healthcare Conference transcript, it reduced its spending base by $1.8 billion in the first nine months of 2018.
Teva or Mylan: Whose Earnings Are Growing Faster?
In its third-quarter earnings investor presentation, Teva Pharmaceutical forecast 2018 non-GAAP EPS of $2.80–$2.95.
Teva or Mylan: Who Has the More Promising Revenue Trajectory?
In its third-quarter earnings investor presentation, Teva Pharmaceutical (TEVA) forecast total 2018 revenue in the range of $18.6 billion–$19.0 billion.
A Financial Overview of Teva Pharmaceutical in December
In the first nine months of 2018, Teva Pharmaceutical’s net revenue fell 16% YoY (year-over-year) to $14.3 billion from $17.0 billion.
Teva Pharmaceutical Stock Rose More than ~8% on December 26
On December 26, Teva Pharmaceutical (TEVA) stock closed at $15.82, a rise of ~8.43% from its close of $14.59 on December 24.
Bausch’s Ultra Multifocal Contact Lenses Get FDA Approval
On December 5, Bausch + Lomb announced that the FDA approved its Ultra multifocal contact lenses for patients with astigmatism.
Ajovy Is a New Growth Driver for Teva Pharmaceutical
On September 14, Teva Pharmaceutical (TEVA) issued a press release announcing FDA approval of humanized monoclonal antibody and anti-calcitonin gene-related peptide (or CGRP) therapy.
A Look at Celgene’s Revlimid Label Expansion Initiatives in 2018
On October 23, 2018, Celgene issued a press release announcing favorable results from open-label Phase 2/3 trial, ECOG E3A06, evaluating Revlimid in the smoldering multiple myeloma (or MM) indication.
How Bausch Health’s Financials Look in November
Bausch Health (BHC) generated revenues of $2.1 billion in the third quarter of this year compared to $2 billion in the third quarter of 2017.
Jazz Pharmaceuticals: How Are Xyrem and Erwinaze Positioned?
Jazz Pharmaceuticals’ Xyrem generated revenues of $357.3 million in the third quarter—compared to $303.9 million in the third quarter of 2017.
What Are Pfizer’s Revenue Drivers?
Pfizer reported revenues of $13.5 billion during the second quarter—4% growth YoY compared to $12.9 million during the second quarter of 2017.
How Novartis’s Sandoz Business Has Been Performing Recently
Sandoz, Novartis’s (NVS) generics business, is a market leader in differentiated generics.
Analysts Are Mostly Positive on Neurocrine Biosciences
On October 4, Neurocrine Biosciences (NBIX) stock closed at $114.58, which is an ~3.79% decline from its October 3 close of $119.09.
GW Pharmaceuticals: Recommendations and Market Capitalization
Wall Street analysts estimate that GWPH stock could increase ~6.7% over the next 12 months.
GlaxoSmithKline ADR’s Performance and Revenues in Q3 2018
Five analysts are currently tracking GlaxoSmithKline ADR. One analyst recommends a “strong buy,” and four analysts recommend a “hold.”
GlaxoSmithKline’s Revenue Was Flat in Second Quarter
GlaxoSmithKline (GSK) reported revenues of 7.3 billion pounds during the second quarter of 2018.
Novartis Reports Growth in Q2 2018 Earnings
Novartis (NVS) released its Q2 2018 earnings on July 18 and surpassed Wall Street analysts’ estimates for revenues and EPS.
Analyst Recommendations for Valeant Pharmaceuticals in July
In July, the FDA accepted Bausch + Lomb’s NDA (New Drug Application) for sub-micron loteprednol etabonate.
Analyst Recommendations for Teva Pharmaceutical in July
As of July 6, according to a recent Reuters survey, 28 analysts are tracking TEVA stock. Six of them have rated it a “buy” or “strong buy.”
How Amgen’s Nplate, Vectibix, and Neupogen Performed in 1Q18
In 1Q18, Amgen’s (AMGN) Nplate revenue grew 16% YoY (year-over-year) to $179 million from $154 million, primarily driven by unit demand.
How Is Novartis’s Xolair Positioned after 4Q17?
In 4Q17, Novartis’s (NVS) Xolair generated revenues of $247 million, which reflected ~14% growth on a year-over-year (or YoY) basis and ~1% growth on a quarter-over-quarter basis.
Will Teva’s Fremanezumab Be Delayed due to Troubles at Celltrion?
Teva Pharmaceutical (TEVA) has a number of key specialty assets that are touted as key long-term growth drivers for the company.
US Generics Market Consolidation Continues to Affect Teva
In 4Q17, Teva experienced a price erosion of ~13% in its generics business.
Teva’s Recent Launch of Generic Solodyn: What You Need to Know
On February 20, 2018, Teva Pharmaceutical announced the US launch of the generic version of Solodyn Extended Release tablets in two strengths.
How the Market Reacted to Teva’s Pricing of Its Generic Syprine
On February 9, 2018, Teva Pharmaceuticals (TEVA) announced the US launch of its generic version of 250 mg Syprine capsules.
Teva Terminates TV-45070 Development Agreement with Xenon
On March 7, Teva and Xenon entered into a mutual agreement to terminate the collaborative development and license agreement they entered into in 2012.
Is the Amazon–Walmart Rivalry About to Spill Over into Israel?
The retail rivalry between Amazon (AMZN) and Walmart (WMT) could spill over into Israel.
Analysts’ Recommendations for Pfizer in March 2018
Pfizer (PFE) surpassed Wall Street analysts’ consensus estimate for EPS (earnings per share) in 4Q17, reporting EPS of $0.62 compared to the estimate of $0.56.
Behind Merck’s Diversified Brands: A Post-4Q17 Update
In 4Q17, Merck’s Singulair reported revenues of $182 million which represents a ~135% decline on a YoY basis and a 13% rise on a QoQ basis.
How Merck’s Bridion and Primaxin Performed in 2017
In 4Q17, Merck’s (MRK) Bridion reported revenues of $209 million, which reflected a ~50% rise on a YoY (year-over-year) basis.
Novartis’s Innovative Medicines Business in 4Q17
Overall, the innovative medicines business accounted for ~67.8% of Novartis’s total revenues.
How Merck’s Cardiovascular Segment Performed in 4Q17 and 2017
In 4Q17, Merck’s Zetia reported revenues of $323 million, which was ~44% lower on a year-over-year basis and a 1% rise on a quarter-over-quarter basis.
Performance of Sanofi’s Business Segments in 4Q17
Sanofi Pasteur reported revenues of ~1.4 billion euros in 4Q17 for 8.7% growth in operating revenues compared to its 4Q16 revenues.
JNJ’s Consumer Products: OTC, Women’s Health, and Wound Care
In 4Q17, JNJ’s Women’s Health segment generated revenues of $262.0 million, which is an ~1.0% decline on a YoY basis.
GlaxoSmithKline’s Pharmaceuticals Business in 4Q17
GlaxoSmithKline’s (GSK) Europe market reported ~1.0% growth in revenues to ~1.0 billion pounds in 4Q17.
How Wall Street Reacted to Berkshire Hathaway Investment in Teva
Teva Pharmaceuticals stock rose ~10.5% during the morning of February 15, 2018, before closing at a rise of ~7.7% on the day.
Novartis’s 4Q17 Earnings: Sandoz Business
Sandoz reported a decline of 4.0% in operating revenues, offset by a 4.0% positive impact of foreign exchange.
Trelegy Ellipta May Emerge as Major Growth Driver for GlaxoSmithKline
Trelegy Ellipta could enable GlaxoSmithKline to compete aggressively with other respiratory players such as Novartis (NVS).
Anoro Ellipta May Boost GlaxoSmithKline’s Respiratory Franchise Revenues
Anoro Elipta earned revenues of close to 233 million pounds in the first nine months of 2017, which is 77% year-over-year (or YoY) growth on a reported basis and 63% YoY growth on a constant exchange rate (or CER) basis.
GlaxoSmithKline Is Focused on Maintaining Leadership in This Segment
To maintain its leadership in the chronic obstructive pulmonary disease (or COPD) segment, GlaxoSmithKline (GSK) has focused on shifting patients away from LAMA monotherapy to its LAMA/LABA bronchodilators.
GlaxoSmithKline Has Developed a Broad Respiratory Portfolio
In 3Q17, GlaxoSmithKline (GSK) reported revenues close to 1.6 billion pounds from the sale of its respiratory products, which is year-over-year (or YoY) growth of 1% on a reported basis.
How Is Novartis’s Subsidiary Sandoz Positioned for 2018?
In 1Q17, 2Q17, and 3Q17, Novartis’s (NVS) subsidiary Sandoz generated revenues of $2.4 billion, $2.5 billion, and $2.6 billion, respectively.
Behind Novartis’s 4Q17 Estimates: Innovative Medicines
The Innovative Medicines segment is expected to report growth in operating revenues for 4Q17.